Trial Outcomes & Findings for NB-001 in Children and Adolescents With 22q11 Deletion Syndrome (NCT NCT05290493)
NCT ID: NCT05290493
Last Updated: 2025-02-10
Results Overview
Type, frequency, severity, and causality of treatment-emergent adverse events (TEAEs),treatment-emergent serious adverse events (TESAEs), clinically significant changes from baseline in laboratory tests, electrocardiograms (ECGs), vital signs, and physical examination findings during treatment with NB-001.
COMPLETED
PHASE2
37 participants
6 weeks (Day 42/ET)
2025-02-10
Participant Flow
Participant milestones
| Measure |
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
|
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
|
|---|---|---|
|
Overall Study
STARTED
|
18
|
19
|
|
Overall Study
COMPLETED
|
15
|
17
|
|
Overall Study
NOT COMPLETED
|
3
|
2
|
Reasons for withdrawal
| Measure |
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
|
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
2
|
2
|
|
Overall Study
Adverse Event
|
1
|
0
|
Baseline Characteristics
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
Baseline characteristics by cohort
| Measure |
Placebo (6 Weeks) Then Washout (1 Week) Then NB-001 (6 Weeks)
n=17 Participants
Subjects received Placebo for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received NB-001 for the subsequent 6-week period (Treatment Period 2).
|
NB-001 (6 Weeks) Then Washout (1 Week) Then Placebo (6 Weeks)
n=17 Participants
Subjects received NB-001 for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week. Subjects then received Placebo for the subsequent 6-week period (Treatment Period 2).
|
Total
n=34 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
12.1 Years
STANDARD_DEVIATION 3.12 • n=99 Participants
|
11.9 Years
STANDARD_DEVIATION 3.30 • n=107 Participants
|
12.0 Years
STANDARD_DEVIATION 3.16 • n=206 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
15 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
13 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
28 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Region of Enrollment
Canada
|
3 participants
n=99 Participants
|
3 participants
n=107 Participants
|
6 participants
n=206 Participants
|
|
Region of Enrollment
United States
|
14 participants
n=99 Participants
|
14 participants
n=107 Participants
|
28 participants
n=206 Participants
|
|
Reproductive Potential
Yes
|
8 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Reproductive Potential
No
|
9 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Safety Analysis Set: Includes all subjects who receive at least one capsule (100 mg) of IP.
Type, frequency, severity, and causality of treatment-emergent adverse events (TEAEs),treatment-emergent serious adverse events (TESAEs), clinically significant changes from baseline in laboratory tests, electrocardiograms (ECGs), vital signs, and physical examination findings during treatment with NB-001.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=34 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Safety and Tolerability of NB-001
CTCAE Grade 4: Life-threatening
|
0 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
TEAE Leading to Premature Withdrawal from the Study
|
0 Participants
|
1 Participants
|
|
Safety and Tolerability of NB-001
Subjects Reporting at Least One TEAE
|
18 Participants
|
24 Participants
|
|
Safety and Tolerability of NB-001
CTCAE Grade 1: Mild
|
14 Participants
|
20 Participants
|
|
Safety and Tolerability of NB-001
CTCAE Grade 2: Moderate
|
4 Participants
|
4 Participants
|
|
Safety and Tolerability of NB-001
CTCAE Grade 3: Severe
|
0 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
CTCAE Grade 5: Causing Death
|
0 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
TEAE Relationship: Not Related
|
12 Participants
|
20 Participants
|
|
Safety and Tolerability of NB-001
TEAE Relationship: Related
|
6 Participants
|
4 Participants
|
|
Safety and Tolerability of NB-001
TEAE Leading to Discontinuation of IP
|
0 Participants
|
1 Participants
|
|
Safety and Tolerability of NB-001
TEAE Requiring Temporary Dose Interruption of IP
|
1 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
TEAE Requiring Dose Reduction of IP
|
0 Participants
|
1 Participants
|
|
Safety and Tolerability of NB-001
TEAE of Special Interest
|
2 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
TEAE Causing Death
|
0 Participants
|
0 Participants
|
|
Safety and Tolerability of NB-001
Subjects Reporting at Least One TESAE
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Full Analysis Set (FAS): Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
The CGI-I scale is a 7-point scale that measures how much a patient's condition has improved or worsened over time. The CGI-I is scored on a scale of 1-7, with a score of 1 indicating "Very much improved" and 7 indicating "Very much worse". The least squares mean of the score on the CGI-I scale at the end of the 6-week treatment period is reported here.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Clinical Global Impression Improvement (CGI-I) Scale
|
3.34 Score on a scale
Standard Error 0.154
|
3.69 Score on a scale
Standard Error 0.154
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
CGI-S: 7-point scale that measures a participant's overall disease severity. A 1-point improvement in the CGI-S scale is an appropriate meaningful change threshold. Possible scores are: 1 = Normal, not at all impaired; 2 = Borderline impaired; 3 = Mildly impaired; 4 = Moderately impaired; 5 = Markedly impaired; 6 = Severely impaired; 7 = Among the most extremely impaired patients.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Clinical Global Impression Severity (CGI-S) Scale
|
4.14 score on a scale
Standard Error 0.121
|
4.12 score on a scale
Standard Error 0.121
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
The PARS is a clinician-rated instrument for assessing severity of anxiety symptoms associated with common anxiety disorders. The first section is a 50-item symptom checklist and the second section is comprised of 7 severity/impairment items reflecting the severity/impairment of all symptoms noted in the first section. The PARS total severity score is calculated as the sum of items 2, 3, 5, 6, and 7 from the second section of the instrument. Each item is rated on a 6-point Likert scale from 0-5 with the higher scores indicating more severe anxiety. The total severity score can range from a minimum value of 0 to a maximum value of 25. Higher scores indicate more severe anxiety. Additionally, per protocol, at baseline, a score of \>12 on the PARS 5-item total severity score (items 2+3+5+6+7) is indicative of psychiatric symptoms in the clinical range for anxiety disorder, and a score of 10 or 11 is indicative of psychiatric symptoms in the subclinical range for anxiety disorder.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Pediatric Anxiety Rating Scale (PARS)
|
7.18 score on a scale
Standard Error 0.728
|
8.14 score on a scale
Standard Error 0.729
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
The ADHD-RS-5 is a parent/guardian reported scale to measure behaviors of children and adolescents with ADHD. It consists of 18 items grouped into two subscales: inattention (items 1-9) and hyperactivity (items 10-18). Each item is scored on a scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms). The total inattention score (reported here) can range from a minimum value of 0 to a maximum value of 27. Higher total inattention scores reflect more severe symptoms.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5) - Inattention Score
|
13.47 score on a scale
Standard Error 0.947
|
13.80 score on a scale
Standard Error 0.941
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Full Analysis Set: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
The ADHD-RS-5 is a parent/guardian reported scale to measure behaviors of children and adolescents with ADHD. It consists of 18 items grouped into two subscales: inattention (items 1-9) and hyperactivity (items 10-18). Each item is scored on a scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms). The total hyperactivity score (reported here) can range from a minimum value of 0 to a maximum value of 27. Higher total hyperactivity scores reflect more severe symptoms.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5) - Hyperactivity Score
|
7.82 score on a scale
Standard Error 0.629
|
8.02 score on a scale
Standard Error 0.623
|
SECONDARY outcome
Timeframe: 6 weeks (Day 42/ET)Population: Includes all subjects in the Enrolled Analysis Set (those who meet all eligibility criteria and consent to participate in study) who have at least one valid post-baseline efficacy evaluation within each treatment period. Subjects are analyzed based on the treatment to which they were randomized in each treatment period.
The SRS-2 identifies the presence and severity of social impairment within the autism spectrum. It is a 65-item, parent-completed questionnaire which incorporates 5 content areas of social deficits. The sum of all items is calculated to provide a maximum total score of 195. However, a total derived T-score is calculated centrally and reported for this trial. A higher T-score indicates more severe impairment. The population mean T-score is 50, with a standard deviation of 10. Thus, a T-score considered within the normal range is 59 or below (i.e., minimum T-score value), and a T-score indicating a severe range is 76 or above (i.e., maximum T-score value). Scores between 60-75 fall into the mild to moderate range.
Outcome measures
| Measure |
NB-001
n=33 Participants
Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
|
Placebo
n=33 Participants
Placebo: Two (2) capsules (inactive, matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
|
|---|---|---|
|
Treatment Effect of NB-001 on the Social Responsiveness Scale, Second Edition (SRS-2)
|
62.42 T-score
Standard Error 1.005
|
63.27 T-score
Standard Error 1.019
|
OTHER_PRE_SPECIFIED outcome
Timeframe: End of Treatment; approximately 13 weeks of trial participationOptional qualitative exit interviews were conducted with clinicians and parent/guardian(s) of subjects who completed the protocol.
Outcome measures
Outcome data not reported
Adverse Events
NB-001
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
NB-001
n=33 participants at risk
Active drug product, NB-001: Two (2) 100 mg capsules administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
NB-001: NB-001 is a non-stimulant modulator of multiple metabotropic glutamate receptors (mGluRs).
|
Placebo
n=34 participants at risk
Placebo: Two (2) capsules (matching NB-001) administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
Placebo: Matching, inactive placebo
|
|---|---|---|
|
Infections and infestations
Nasopharyngitis
|
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
11.8%
4/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Infections and infestations
Upper respiratory tract infection
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Psychiatric disorders
Insomnia
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
17.6%
6/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Psychiatric disorders
Irritability
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Psychiatric disorders
Anxiety
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
8.8%
3/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Gastrointestinal disorders
Vomiting
|
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
0.00%
0/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
2.9%
1/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
General disorders
Fatigue
|
9.1%
3/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
2.9%
1/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
General disorders
Pyrexia
|
6.1%
2/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
|
Nervous system disorders
Headache
|
3.0%
1/33 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
5.9%
2/34 • Approximately 21 weeks: Adverse Events (AEs) were collected from the time of signing the Informed Consent Form (ICF) to the End of Trial Visit (Day 119).
Treatment-emergent AEs are defined as those AEs with onset after the first dose of IP or existing events that worsened after the first dose during the study. Any AE that occurred between the date of ICF signature and the date/time of first IP administration was considered a pre-treatment-emergent AE. At each level of summarization (any event, system organ class, and preferred term), subjects reporting more than one AE are counted only once.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place